Nasal Epithelial Genetic and Single Cell RNA COVID-19 Study (CIPOLLINI)

Nasal CIliated EPithelial Genetic And Single Cell RNA prOfiLes of miLd, Severe and Very Severe COVID-Nineteen patIents (CIPOLLINI) Study

Rationale:

The investigators hypothesize that genetics and the nasal epithelial response to SARS-CoV2 are critical determinants of the immune response to viral infection, and predict clinical outcome in COVID-19 patients.

Objective:

The main objective is to assess whether genetic background and/or the nasal epithelial gene expression in response to SARS-CoV2 is different in patients with mild, severe or very severe disease. The secondary goal of this study is to investigate a) the role of the ACE2-AngII system during SARS-CoV2 in relation to outcome b) the long-term consequences of mild, severe, and very severe COVID-19 infection c) the association between mild, severe and very severe COVID-19 with clinical & molecular markers of disease progression d) whether the faeces microbiome, virome or metabolomics profile predicts clinical outcome in COVID-19 patients and e) to investigate whether pre-existing antibodies towards other coronaviruses play a role in severe disease development.

Study design:

Prospective open label clinical observational study. In this study samples will be collected from 150 COVI-19 patients ( 50 mild (group 1), 50 severe (group 2) and 50 very severe (group 3) ). Blood, nasal brushes and stool will be collected for all groups at hospital admission and 3 months after recovery, and for groups 2 & 3 at day 3, at day 14, and before detubation

Study population:

A total of 150 patients diagnosed with COVID-19 will be included. The investigators aim for 50 patients per group, divided over 3 groups:

Group 1 Patients with mild disease who tested positively for SARS-CoV2 infection, but only experience mild symptoms and do not need hospitalization.

Group 2 Patients with severe disease admitted to hospital, without the need to be admitted to the intensive care.

Group 3 Patients with very severe disease admitted to intensive care, who require mechanical ventilation.

Main study parameters/endpoints:

The primary endpoint of this study is the identification of genes, pathways and cell populations that associate with clinical outcome and disease progression in mild, severe and very severe COVID-19 patients.

Study Overview

• Status: Withdrawn
• Conditions: COVID-19

Detailed Description

Rationale:

The currently ongoing world-crippling pandemic with the new SARS-CoV2 virus shows the desperate and urgent need for a better understanding of the biological pathways activated by the virus inducing Coronavirus disease 2019 (COVID-19) in infected patients. A subset of COVID-19 patients develop very severe respiratory symptoms requiring hospital admission with or without the need for mechanical ventilation, whereas others experience mild flu-like symptoms. The biological mechanisms underlying this striking difference in clinical outcome and the long term consequences are unknown, yet a genetic factor seems likely. SARS-CoV2 enters cells via the ACE2 receptor and the activating protease TMPRSS2 which have recently been shown to be strongly enriched in nasal epithelium. The investigators hypothesize that genetics and the nasal epithelial response to SARS-CoV2 are critical determinants of the immune response to viral infection, and predict clinical outcome in COVID-19 patients.

Objective:

The main objective is to assess whether genetic background and/or the nasal epithelial gene expression in response to SARS-CoV2 is different in patients with mild, severe or very severe disease. The secondary goal of this study is to investigate a) the role of the ACE2-AngII system during SARS-CoV2 in relation to outcome b) the long-term consequences of mild, severe, and very severe COVID-19 infection c) the association between mild, severe and very severe COVID-19 with clinical & molecular markers of disease progression d) whether the faeces microbiome, virome or metabolomics profile predicts clinical outcome in COVID-19 patients and e) to investigate whether pre-existing antibodies towards other coronaviruses play a role in severe disease development.

Study design:

Prospective open label clinical observational study. In this study samples will be collected from 150 COVI-19 patients ( 50 mild (group 1), 50 severe (group 2) and 50 very severe (group 3) ). Blood, nasal brushes and stool will be collected for all groups at hospital admission and 3 months after recovery, and for groups 2 & 3 at day 3, at day 14, and before detubation. Study subjects will be retrospectively allocated to the groups.

Study population:

A total of 150 patients diagnosed with COVID-19 will be included. The investigators aim for 50 patients per group, divided over 3 groups:

Group 1 Patients with mild disease who tested positively for SARS-CoV2 infection, but only experience mild symptoms and do not need hospitalization.

Group 2 Patients with severe disease admitted to hospital, without the need to be admitted to the intensive care.

Group 3 Patients with very severe disease admitted to intensive care, who require mechanical ventilation.

Main study parameters/endpoints:

The primary endpoint of this study is the identification of genes, pathways and cell populations that associate with clinical outcome and disease progression in mild, severe and very severe COVID-19 patients.

• Study Type: Observational

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

• Sampling Method: Probability Sample

Study Population

Group 1 Patients with mild disease who tested positively for SARS-CoV2 infection, but only experience mild symptoms and do not need hospitalization.

Group 2 Patients with severe disease admitted to hospital, without the need to be admitted to the intensive care.

Group 3 Patients with very severe disease admitted to intensive care, who require mechanical ventilation.

Description

Inclusion Criteria:

1. Patients have to be tested (PCR) positive for SARS-CoV2 infection.
2. Provided written informed consent

Exclusion Criteria:

1. No comprehension of Dutch or English language

Study Plan

How is the study designed?

Number of groups / cohorts

3

Cohorts and Interventions

Group / Cohort
Mild COVID-19; Patients with mild disease who tested positively for SARS-CoV2 infection, but only experience mild symptoms and do not need hospitalization.
Severe COVID-19; Patients with severe disease admitted to hospital, without the need to be admitted to the intensive care.
Very Severe COVID-19; Patients with very severe disease admitted to intensive care, who require mechanical ventilation.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Nasal epithelial transcriptional response to SARS-CoV2	To assess how the nasal epithelial transcriptional response to SARS-CoV2 is different in patients with mild, severe, or very severe disease.	Observational-baseline

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
ACE2-AngII system	To assess the role of the ACE2-AngII system during SARS-CoV2 in relation to disease outcome (mild, severe, very severy COVID)	Observational-baseline

Collaborators and Investigators

• Sponsor: University Medical Center Groningen
• Investigators: Principal Investigator: Dirk-Jan Slebos, MD PhD, UMCG, Department of pulmonology; Principal Investigator: Janesh Pillay, MD PhD, UMCG, Intensive Care Medicine

Study record dates

Study Major Dates

• Study Start (Actual): November 1, 2022
• Primary Completion (Actual): November 1, 2022
• Study Completion (Actual): November 1, 2022

Study Registration Dates

• First Submitted: April 20, 2020
• First Submitted That Met QC Criteria: April 20, 2020
• First Posted (Actual): April 24, 2020

Study Record Updates

• Last Update Posted (Actual): November 4, 2022
• Last Update Submitted That Met QC Criteria: November 1, 2022
• Last Verified: November 1, 2022

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Coronavirus Infections; Coronaviridae Infections; Nidovirales Infections; RNA Virus Infections; Virus Diseases; Infections; Respiratory Tract Infections; Respiratory Tract Diseases; Pneumonia, Viral; Pneumonia; Lung Diseases; COVID-19
• Other Study ID Numbers: CIPOLLINI

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: UNDECIDED
• IPD Plan Description: Data can be shared on request.

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No